Hope for halting rogue bone growth in rare disease
NCT ID NCT06724562
Summary
This study is observing whether existing anti-inflammatory drugs (anakinra or canakinumab) can help control severe FOP, a rare genetic disorder that causes muscle and soft tissues to turn into bone. Researchers will follow 11 patients, aged 6-30, who have very frequent painful flare-ups, for up to a year after they start the medication. The goal is to see if the treatment reduces flare frequency, stops new bone formation, and improves mobility to gather data for a larger future trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCSF
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.